MyHealthChecked has announced that its “disposal of Concepta Diagnostics Limited completed… the board changes detailed in the notification of 14 October 2025 have taken effect” and a change of name. What of that from the valuation at a current 9.5p offer price for the shares?
Writing on consumer home-testing healthcare company MyHealthChecked (MHC) last week with the shares at the now-equivalent of 19.5p (following a 15-to-1 shares consolidation in between), we concluded positively with there having been looking exciting news flow potential imminently. Now an “Agreement with Boots for extended retail launch” announcement – and the shares are currently up to 26p, almost 2p in old money.
Consumer home-testing healthcare company MyHealthChecked (MHC) has announced its results for the 2022 calendar year and a proposed shares consolidation.
Consumer home-testing healthcare company MyHealthChecked (MHC) has announced results for the first half of 2022 including noting a new portfolio and associated launches which it is “excited to share with the market in Q4”.
MyHealthChecked (MHC) has announced that four of its cheek-swab DNA at-home wellness tests are now available to purchase through the Amazon UK site (with Glucose Management expected to follow), emphasising that “following the success of our partnership with the UK's top high street pharmacy retailers for our COVID testing service, we have seen the real value that additional retail partners can bring to the business by broadening our customer base and significantly increasing our market share”.
MyHealthChecked (MHC) has announced half-year trading “has been stronger than expected and ahead of management budgets”, that increase in COVID-19 infection rates has led to a significant increase in demand for lateral flow test kits in recent weeks and that it is “very pleased” with the feedback around its recently-launched wellness tests – for which it has now also announced availability on Amazon.
MyHealthChecked (MHC) has revealed that, in the first six months of 2022, trading was stronger than expected – as the company launches its new at-home "wellness tests".
In September, we concluded that, with shares in MyHealthChecked (MHC) around 3p: ‘we hope you followed our average down call at 0.8p and top-sliced at well over 3p. We may revisit, but for now, we can’t see this racing away. It is, therefore, time to say goodbye to your shares’. Now, with the shares at 1.9p, it looks like time to revisit.
Today we are told via RNS Reach “New Briefing Note from SEAL” on MyHealthChecked (MHC). Sadly it is SEAL Research not Seal the popular singer, otherwise known as Henry Olusegun Adeola Samuel, or a whiskered fellow from London zoo as both of the would have more credibility than the paid for rampers taking centre stage today. It is SEAL that has issued the release and this is another big sell signal for MyHealthChecked. It is a red flag and I am glad to be out.
Events have moved apace since this appeared.These shares are not a buy as explained HERE. MyHealthchecked (MHC) has flagged up what we loyal shareholders can all expect to hear about over the next month or so. First up on September 29 when we will get the interim results to June 30 and a Q3 trading update.
MyHealthChecked (MHC) has made an RNS announcement including that it is “delighted” to now have in place accreditation across its COVID-19 testing service. How delighted should it be with recent developments?
Earlier today, I broke the news that MyHealthChecked (MHC) where I am, of course, a loyal shareholder is now selling its covid tests via Lloyds Pharmacies. We do not know if it is just online or in any or all of the company’s 1400 stores but this is clearly material. MyHealthchecked has announced nothing. At one point earlier, the shares were up 38%. My job as a journalist is to break news which I did. I will not trade any shares until the company comes clean and probably not even then. The company’s duties under AIM listing rules include maintaining an orderly market in its shares. It has failed in that. I have written to the Oxymorons at AIM Regulation demanding an enquiry and a statement.
This is massive. Lloyds has 1400 stores across the UK. And as you can see HERE, it is now selling the MyHealthChecked (MHC) covid test. Boots is selling the test from more than 500 stores and that deal plus sales from MyHealthChecked's own portal managed to drive sales of c£3 million in May and June alone. So gaining this additional distribution (plus that from partnering with EasyJet) is surely highly material. Why no RNS?
